logo

For the Inventor, By the Inventor

Gaithersburg, MD, United States of America

Novavax, Inc.


USPTO Granted Patents = 65

% Expired Patents = 3.1



Trademarks = 7

Forward Citations = 959

Loading Chart...
Loading Chart...

38 inventors (with patents filed for the assignee):

goldMedal Gale Smith (44 out of 45 patents)

silverMedal Peter M Pushko (32 out of 58 patents)

bronzeMedal Michael J Massare (24 out of 26 patents)

4.  Ye Liu (17 out of 35 patents)

5.  Jing-Hui Tian (15 out of 23 patents)

6.  Kutub Mahmood (13 out of 13 patents)

7.  Yingyun Wu (12 out of 12 patents)

8.  Rick Bright (11 out of 11 patents)

9.  Jinyou Zhang (11 out of 11 patents)

10.  Robin A Robinson (11 out of 12 patents)

11.  D Craig Wright (11 out of 16 patents)

12.  Bin Zhou (9 out of 9 patents)

13.  Sarathi Boddapati (6 out of 7 patents)

14.  Gregory M Glenn (5 out of 36 patents)

15.  Erica Shane (4 out of 15 patents)


Core Competencies:
Coronavirus Vaccine
RSV F Proteins
Influenza VLPs
Vaccine Compositions
Immunogenicity
Multivalent Vaccines
Stability
Chimeric VLPs
Antiviral Activity
Lipid Vesicles
Adjuvants
Nanoparticles

65 patents:

1. 12691171 - CORONAVIRUS VACCINE FORMULATIONS (2026-07-28),
2. 12491241 - CORONAVIRUS VACCINE FORMULATIONS (2025-12-09),
3. 12472246 - CORONAVIRUS VACCINE FORMULATIONS (2025-11-18),
4. 12357684 - Modified RSV F proteins and methods of their use (2025-07-15),
5. 12257297 - Vaccine compositions having improved stability and immunogenicity (2025-03-25),
6. 11938179 - Methods and compositions for inducing immune responses against (2024-03-26),
7. 11896664 - Corona virus vaccine formulations (2024-02-13),
8. 11896662 - Multivalent influenza nanoparticle vaccines (2024-02-13),
9. 11541112 - Coronavirus vaccine formulations (2023-01-03),
10. 11446374 - Modified RSV F proteins and methods of their use (2022-09-20),
11. 11364294 - Vaccine compositions having improved stability and immunogenicity (2022-06-21),
12. 11278612 - Multivalent influenza nanoparticle vaccines (2022-03-22),
13. 11253586 - Coronavirus vaccine formulations (2022-02-22),
14. 11253585 - Vaccine compositions having improved stability and immunogenicity (2022-02-22),
15. 11123419 - Methods and compositions for inducing immune responses against Clostridium difficile (2021-09-21),
Company Overview
Novavax, Inc., based in Gaithersburg, Maryland, specializes in the development and manufacturing of innovative vaccine formulations. The company focuses on creating vaccines for various infectious diseases, including those targeting coronavirus, respiratory syncytial virus (RSV), and influenza. Novavax employs advanced technologies such as virus-like particles (VLPs) and multivalent vaccine compositions to enhance immunogenicity and stability, positioning itself as a key player in the global vaccine landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Novavax, Inc. USPTO Patent Assignee Logo
65 Patents

#4 in Gaithersburg, MD

#51 in Maryland

#5,614 in US

#11,344 in the World

Gaithersburg, MD (US)
Gaithersburg, MD, United States of America

Novavax, Inc.

Forward Citations = 959

38 inventors:

goldMedal Gale Smith (44 out of 45 patents)

silverMedal Peter M Pushko (32 out of 58 patents)

bronzeMedal Michael J Massare (24 out of 26 patents)

4.  Ye Liu (17 out of 35 patents)

5.  Jing-Hui Tian (15 out of 23 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Novavax, Inc.. Retrieved from https://idiyas.com/company/novavax

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…